All material subject to strictly enforced copyright laws. © 2021 Euromoney Institutional Investor PLC group
EquityEquity - Follow-ons and Rights issues

Cellectis US cap raise closes historic year for biopharma


Cellectis, the French gene-editing company, has launched a $100m US capital raising to help fund its research and development operations. The sector has had a record year for issuance in 2020, as the Covid-19 pandemic has concentrated minds on global healthcare innovation.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree